SEC Company Response from ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670) (ALNY) — Dec 8, 2010
ALNYLAM PHARMACEUTICALS, INC. (ALNY) (CIK 0001178670)
Date: Dec. 8, 2010 · CIK: 0001178670 · Accession: 0000950123-10-111845
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-50743
Letter
Division of Corporate Finance Attention: Johnny Gharib Alnylam Pharmaceuticals, Inc. Form 10-K Filed February 26, 2010 File No. 000-50743
Re:
Dear Mr. Gharib:
This letter relates to the letter, dated December 2, 2010 (the “Letter”), from Jeffrey Riedler of the Staff of the U.S. Securities and Exchange Commission to John M. Maraganore, Chief Executive Officer of Alnylam Pharmaceuticals, Inc. (the “Company”).
On behalf of the Company, and as discussed by telephone with you on December 7, 2010, this letter confirms that the Company will respond to the Letter on or before January 13, 2011.
If you require additional information, please do not hesitate to contact me at 617-526-6443.
Sincerely,
/s/ Clark W. Petschek
Show Raw Text
CORRESP
1
filename1.htm
corresp
December 8, 2010
By EDGAR Submission
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E., Mail Stop 6010
Washington, D.C. 20549
Attention: Johnny Gharib
Re:
Alnylam Pharmaceuticals, Inc.
Form 10-K
Filed February 26, 2010
File No. 000-50743
Dear Mr. Gharib:
This letter relates to the letter, dated December 2, 2010 (the “Letter”), from Jeffrey Riedler of
the Staff of the U.S. Securities and Exchange Commission to John M. Maraganore, Chief Executive
Officer of Alnylam Pharmaceuticals, Inc. (the “Company”).
On behalf of the Company, and as discussed by telephone with you on December 7, 2010, this letter
confirms that the Company will respond to the Letter on or before January 13, 2011.
If you require additional information, please do not hesitate to contact me at 617-526-6443.
Sincerely,
/s/ Clark W. Petschek
Clark W. Petschek
cc:
Philip T. Chase, Esq.
Lia Der Marderosian, Esq.